Latest From Insulet Corp.
CES 2020: Panel Discusses Health Care In 2040 – Empowered Consumer, Digital Transformation, Data Sharing, Open Source
An expert panel at CES 2020 discussed Deloitte's vision for health care in 2040, with the empowered consumer managing their own health, enabled by a new ecosystem of secure, open access to data and "nudges" to change behaviors. Consulting firm Deloitte foresees outside disruptors dismantling the traditional health-care system, but panelists from Johnson & Johnson and Anthem flexed their muscles.
Tandem Diabetes Care received FDA clearance for its Control-IQ technology for use with Tandem's t:slim X2 insulin pump and Dexcom's G6 continuous glucose monitoring system, making it the first hybrid closed-loop system to deliver automatic correction boluses and adjust background insulin levels to help prevent high and low blood sugars.
Market Intel: Bigfoot Biomedical, Beta Bionics Getting Pumped To Introduce Next-Gen Artificial Pancreas
The insulin pump market, which is dominated by four major players, is facing rising competition from smaller, innovative companies. This second part of a two-part series focuses on five emerging companies: Beta Bionics, Bigfoot Biomedical, Diabeloop, EOFlow and Ypsomed.
The disruptive medtech M&A of recent years was not matched in the past year for volume, but there were isolated outbreaks of major activity, as shown in our company rankings.
In Vitro Diagnostics
- Glucose Testing
- Infusion Therapy Equipment and Supplies
- Monitoring Equipment & Devices
- Drug Delivery
- Therapeutic Areas
- Metabolic Disorders
- North America
- Parent & Subsidiaries
- Insulet Corp.
- Senior Management
Shacey Petrovic, Pres. & CEO
Wayde McMillan, EVP, CFO
Eric Benjamin, SVP, R&D
- Contact Info
Phone: (978) 600-7000
100 Nagog Park
Acton, MA 01720
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.